ImVacS, The Immunotherapies and Vaccine Summit, brings together a global audience of vaccine researchers and developers of cancer immunotherapies for four focused meetings that explore the frontiers of immunology as the basis for patient treatment.
Part 1 of the 9th annual “Novel Vaccines” meeting addresses “Adjuvants, TLRs and DNA Vaccines,” while Part 2 explores “Emerging Vaccine Technologies.” The 2nd annual “Immunomodulatory Therapeutic Antibodies for Cancer” meeting examines developments in the models and tools used in developing these emerging drug products, while the inaugural “Combination Cancer Immunotherapy” meeting focuses on the application of these antibody programs in combination with other treatment modalities. Target Discovery for T Cell Therapy Symposium will bring together leading academic and industry researchers to discuss how to find and validate suitable targets and antigens for t cell therapies.
The Regulatory Outlook for Future Vaccine Adjuvants
Norman W. Baylor, Ph.D., President and CEO, Biologics Consulting Group, Inc.
Synthetic Genomics to Address Emerging Threats and Global Supply Challenges
Bolyn Hubby, Ph.D., Senior Director, Head, Vaccine and Phage R&D, Synthetic Genomics Vaccines, Inc.
Putting Cancer in Check with Novel Immunomodulatory Strategies
Michael A. Postow, M.D., Assistant Attending Physician, Melanoma and Immunotherapeutics Service, Memorial Sloan-Kettering Cancer Center
Update from 2014 ASCO Meeting: Clinical Trials for Immunotherapy Combinations
Omid Hamid, M.D., Director, Melanoma Center, Angeles Clinic and Research Institute
Each year, ImVacS brings vaccine professionals together from around the world to discuss the crucial issues surrounding vaccine development. Along with presenting a snapshot of where vaccines stand today, the meeting also provides an important venue for networking, information exchange, and establishing collaborations.
The “Novel Vaccines” meeting explores how vaccine development is being innovated in order to create more efficacious vaccines, such as using Systems Biology or Reverse Vaccinology. The use of adjuvants – their safety and mode of action – will also be discussed, as will DNA vaccines, Toll-Like Receptors, and novel modes of delivery. In addition, how improved vaccines are targeting infectious diseases will be addressed and updated.